We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...
Hosted on MSN12h
Wells Fargo Downgrades Exelixis (EXEL)Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...
Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...
Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other Renaissance Technologies portfolio’s top stock picks. The American quant hedge fund ...
HPV16+ Cancers Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback